Article info

Download PDFPDF
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)

Authors

  1. Correspondence to Dr Philipp Harter, Gynecology and Gynecologic Oncology, AGO & Ev. Kliniken Essen-Mitte, Essen 45136, Germany; p.harter{at}gmx.de
View Full Text

Citation

Harter P, Pautier P, Van Nieuwenhuysen E, et al
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)

Publication history

  • Accepted June 5, 2020
  • First published June 30, 2020.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.